Even so, 81% of patients saw at least 1 new or worsened symptom while on the DAA treatment or within 4 weeks of completing therapy. When ribavirin was co-administered, the odds of adverse events increased, the researchers found.
Serious adverse events affected 17% of the patients, although only 8% discontinued treatment. The degree of CKD did not change the rate of side effects, the team found.
Previous studies of sofosbuvir have shown SVR rates approaching 100% in some populations, but the lower rate in this study had a reasonable explanation, Dr. Sise said.
“This study looked at all patients treated so it included all genotypes,” Sise said. “Patients with genotypes 3 are much harder to cure.”
In addition, many of the patients received sofosbuvir and ribavirin. This therapy isn’t as effective as newer, more potent, combination DAAs, Dr. Sise said. She continued, “I suspect that these are the reasons for the SVR rate that is lower than what is typically seen in the general population.”
Larger studies are needed to determine if eradication of HCV with DAAs slows or prevents progression to end-stage kidney disease in patients with CKD and HCV, researchers wrote. In fact, the according to Dr. Sise, “We are now examining a population of 2000 patients treated with DAAs to determine the effect of DAAs on kidney function.
Disclosures: Dr. Sise and others reported research grants from Gilead, AbbVie, Merck & Co., Bristol-Myers Squibb and Janssen. Some of the authors also participated on drug makers’ scientific advisory boards.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.